Biotech Values

[linhdtu]

Heck, who can argue with that ?

I was one who piled into enta in 2013 even as the pps was falling prior to the P3 results and as luck would have it, sold out at a reasonable high level before the script number trend for abbvie/enta became clear.

i also would agree with you regarding rvnc, although i am dilly dallying about running up my stake because i think i still have time before yr end 2017 P3 results.

however, going back to enta now wrt to NASH, does the data/results to date for edp305 give you enough of a clear understanding of its MOA ?

one thing i have always like/respect about enta is lack of mgt selling unlike other biotechs . they indeed are taking the same risk as i do buying their shares. i can't really ask for more than that.